HDAC9 and posterior cortical atrophy: HDACs are often overexpressed in PCa as well, but while HDAC inhibitors seem to have promising results in hematological malignancies, phase II clinical trials of HDAC inhibitors (vorinostat, pracinostat, panobinostat, and romidepsin) in PCa have failed due to toxicity or disease progression [168].